기사

[BioTimes] At the recent academic conference of the Korean Society of Laser Dermatology and Hair Loss (hereinafter referred to as "Daepimo"), regenerative medicine emerged as a new hot topic in the aesthetic treatment market. Technologies that aim for fundamental skin regeneration and treatment, beyond simple cosmetic improvements, are attracting attention. The blood-based regenerative platform "GFC (Growth Factor Concentrate)" presented by biotechnology company Prodizen has captured the attention of medical professionals.

At this conference, Prodizen highlighted its GFC solution, which overcomes the limitations of conventional PRP (platelet-rich plasma) treatments and maximizes regenerative effects. Prodizen's GFC, in particular, differentiates itself by moving beyond the traditional approach of simply focusing on platelet concentration, focusing instead on the "absolute signal amount" and delivery structure of growth factors involved in actual treatment.

GFC's core technology lies in its unique plasma separation system, which enables efficient PRP extraction. This system quickly and easily separates effective components from blood, ensuring consistency and reproducibility of the procedure.

During the event, the Prodigen booth was lined with medical professionals with a keen interest in skin anti-aging and regenerative treatments, and lively and practical discussions took place on the clinical application of GFC and the composition of protocols.

A medical professional who visited the Prodizen booth said, “Unlike existing treatments, it was impressive that they presented clear ingredient mechanisms and clinical protocols,” and added, “It was beneficial to be able to discuss the possibility of using it in actual clinical settings and the effective treatment structure beyond a simple product introduction.”

A Prodizen official stated, “Through this academic conference, we were able to confirm that GFC technology, approached from a regenerative medicine perspective, is receiving keen interest from medical professionals,” and “We will continue to expand educational and academic exchanges with global partners to broaden the market dominance of our blood-based regenerative platform.”

Meanwhile, Prodizen is currently participating in major domestic academic societies and collaborating with overseas medical professionals and partners to propose solutions tailored to each country's clinical environment. With this participation in Dapimoh, Prodizen plans to further strengthen its domestic and international academic marketing efforts.

[Biotimes=Reporter Jeong Min-ah] news@biotimes.co.kr

Source: Biotimes (http://www.biotimes.co.kr)